Champions Oncology Announces Agreement with Weill Cornell Medicine

Rhea-AI Summary

Champions Oncology (Nasdaq: CSBR) has announced a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing. This collaboration grants Champions Oncology exclusive rights to distribute and commercialize Weill Cornell Medicine's hematological patient-derived xenograft (PDX) models.

The PDX models were developed by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine. Champions Oncology will serve as a repository to distribute these models to academic institutions worldwide, enhancing its position in the heme-oncology field.

This strategic partnership aligns with Champions Oncology's commitment to providing advanced preclinical oncology solutions and strengthens its portfolio in hematological research. The collaboration is expected to facilitate rapid and scalable access to these unique PDXs for both biopharma partners and academic institutions.

Positive

• Exclusive rights to distribute and commercialize Weill Cornell Medicine's hematological PDX models
• Expansion of Champions Oncology's portfolio in the heme-oncology field
• Potential for increased revenue through distribution to academic institutions and biopharma partners
• Collaboration with a renowned expert in hematological PDX models

Negative

• None.

Insights

Biotech Industry Analyst

This licensing agreement between Champions Oncology and Weill Cornell Medicine is a significant development in the heme-oncology field. The exclusive rights to distribute and commercialize Weill Cornell's hematological patient-derived xenograft (PDX) models will substantially enhance Champions' portfolio and service offerings. This collaboration aligns with the growing trend of academia-industry partnerships in biotech, potentially accelerating drug discovery and development processes. For Champions Oncology, this deal could lead to increased revenue streams and solidify its market position in preclinical oncology solutions. However, investors should note that the exclusivity is time-, which may impact long-term value. The partnership with a prestigious institution like Weill Cornell also adds credibility to Champions' platform, potentially attracting more biopharma clients. Overall, this agreement represents a positive step for Champions Oncology in expanding its capabilities and market reach in the competitive oncology research space.

Oncology Research Specialist

The acquisition of Weill Cornell Medicine's hematological PDX models by Champions Oncology is a noteworthy advancement in preclinical oncology research. These models, developed by the renowned Dr. Giorgio Inghirami, are likely to be of high quality and clinical relevance. PDX models are important in drug development as they closely mimic human tumor biology, providing more predictive results than traditional cell line models. By offering these models, Champions can now provide a more comprehensive suite of tools for hematological cancer research, potentially attracting more pharmaceutical companies for drug testing services. This could lead to faster and more efficient drug discovery processes in blood cancers, an area of significant unmet medical need. The agreement also facilitates broader access to these models for academic institutions, which could accelerate basic research in hematological malignancies. This collaboration exemplifies the growing importance of translational research in oncology and the value of academic-industry partnerships in advancing cancer therapeutics.

HACKENSACK, NJ / ACCESSWIRE / October 16, 2024 / Champions Oncology, Inc. (Nasdaq:CSBR), a leader in the development of advanced preclinical oncology solutions, is pleased to announce a licensing agreement with Weill Cornell Medicine through the Center for Technology Licensing (CTL), part of Enterprise Innovation at Weill Cornell Medicine. This strategic collaboration will allow Champions Oncology to distribute and commercialize Weill Cornell Medicine's extensive bank of hematological patient-derived xenograft (PDX) models, generated by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at the institution and a member of the Englander Institute for Precision Medicine and Sandra and Edward Meyer Cancer Center.

Through this agreement, Champions Oncology will hold exclusive rights, for a limited time, to offer services leveraging Weill Cornell Medicine's models, and will serve as a repository to distribute these models to academic institutions worldwide. This collaboration enhances Champions Oncology's commitment to providing cutting-edge solutions in the heme-oncology space.

"We are thrilled to be chosen to collaborate with Weill Cornell Medicine," said Ronnie Morris, MD, CEO at Champions Oncology. "Dr. Inghirami is globally renowned for his expertise in generating hematological PDX models. The addition of these models to our portfolio will further solidify our position as a leader in the heme-oncology field. Our extensive experience in commercializing clinically relevant, pretreated hematological models will ensure rapid and scalable access to these unique PDXs for both our biopharma partners and academic institutions."

The Center for Technology Licensing at Weill Cornell Medicine played a crucial role in negotiating the licensing agreement and brokering this relationship with Champions Oncology as part of Enterprise Innovation's mission to accelerate the best of biomedical innovation to market and translate groundbreaking research by Weill Cornell Medicine faculty into transformational care solutions. Enterprise Innovation provides a bridge between academic researchers and industry stakeholders.

About Champions Oncology

Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit www.ChampionsOncology.com.

Media Inquiries:

Rachel Bunting, MS, MBA
VP, Global Marketing
Marketing@ChampionsOncology.com

Website: https://www.championsoncology.com/
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
X: @ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/

SOURCE: Champions Oncology, Inc.

View the original press release on accesswire.com

FAQ

What is the new licensing agreement announced by Champions Oncology (CSBR)?

Champions Oncology (CSBR) has announced a licensing agreement with Weill Cornell Medicine to distribute and commercialize their hematological patient-derived xenograft (PDX) models.

How will the agreement with Weill Cornell Medicine benefit Champions Oncology (CSBR)?

The agreement will allow Champions Oncology (CSBR) to expand its portfolio in the heme-oncology field, potentially increasing revenue through distribution of unique PDX models to academic institutions and biopharma partners.

Who developed the hematological PDX models licensed by Champions Oncology (CSBR)?

The hematological PDX models were developed by Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine at Weill Cornell Medicine.

What role will Champions Oncology (CSBR) play in distributing the Weill Cornell Medicine PDX models?

Champions Oncology (CSBR) will serve as a repository to distribute these models to academic institutions worldwide and will have exclusive rights to offer services leveraging these models for a time.